| Case Number | 12098 |
| Request Date | 03/09/2026 |
| Completion Date | 25/09/2026 |
Details of the Request
Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:
- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Apremilast [Generic]
- Baricitinib [Olumiant]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Golimumab Biosimilar
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tocilizumab Biosimilars
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]
- Ustekinumab Biosimilar
Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs:
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Golimumab [Simponi]
- Golimumab Biosimilar
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Secukinumab [Cosentyx]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
Details of the Response
Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:
- Abatacept [Orencia] = 35
- Adalimumab [Humira] = 27
- Adalimumab Biosimilars = 343
- Apremilast [Otezla] = 0
- Apremilast [Generic] = 0
- Baricitinib [Olumiant] = 7
- Bimekizumab [Bimzelx] = 1
- Certolizumab [Cimzia] = 34
- Etanercept [Enbrel] = 1
- Etanercept Biosimilars = 119
- Filgotinib [Jyseleca] = 12
- Golimumab [Simponi] = 7
- Golimumab Biosimilar = 0
- Guselkumab [Tremfya] = 3
- Infliximab [Remicade] = 0
- Infliximab Biosimilars = 3
- Ixekizumab [Taltz] = 0
- Risankizumab [Skyrizi] = 2
- Rituximab [MabThera] = 0
- Rituximab Biosimilars = 28
- Sarilumab [Kevzara] = 0
- Secukinumab [Cosentyx] = 53
- Tocilizumab [Ro Actemra] = 39
- Tocilizumab Biosimilars = 0
- Tofacitinib [Xeljanz] = 3
- Upadacitinib [Rinvoq] = 12
- Ustekinumab [Stelara] = 0
- Ustekinumab Biosimilar = 7
Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs:
- Adalimumab [Humira] = 3
- Adalimumab Biosimilars = 30
- Bimekizumab [Bimzelx] = 0
- Certolizumab [Cimzia] = 2
- Etanercept [Enbrel] = 0
- Etanercept Biosimilars = 6
- Golimumab [Simponi] = 1
- Golimumab Biosimilar = 0
- Infliximab [Remicade] = 0
- Infliximab Biosimilars = 1
- Ixekizumab [Taltz] = 0
- Secukinumab [Cosentyx] = 9
- Tofacitinib [Xeljanz] = 0
- Upadacitinib [Rinvoq] = 2



